Shiyao Group (01093): Phase II clinical trial of SYH2069 injection for the treatment of adult type 2 diabetes officially launched at the first research center in China

According to Zhitong Finance App, Shiyao Group (01093) announced that the phase II clinical trial (SYH2069-003) of the SYH2069 injection (“product”) developed by the group to treat adult type 2 diabetes () has been officially launched at the first research center in China.

This product is a novel fatty acid-modified polypeptide long-acting glucagon-like peptide-1 receptor (“GLP-1R”) and a glucose-dependent insulin-promoting polypeptide receptor (“GIPR”) dual-target biased agonist. It is designed to selectively activate GLP-1R and GIPR to promote insulin secretion in a glucose-dependent manner. It is expected to reduce sugar and weight loss by suppressing appetite, delaying gastric emptying, increasing satiety, and reducing calorie intake.

Furthermore, by selectively activating GLP-1R and the cyclic adenosine phosphate (cAMP) signaling pathway downstream of GIPR, the product can avoid receptor internalization and desensitization due to beta-arrestin (β-arrestin) recruitment, thereby enhancing its activity and extending the duration of efficacy. Preclinical studies have shown that the product shows good target activity and controllable safety characteristics.

The Group obtained the “Drug Clinical Trial Approval Notice” issued by the China Drug Administration (“State Drug Administration”) of the People's Republic of China in December 2025 for the indication of overweight or obesity, and initiated relevant phase I clinical trials after approval; these tests initially demonstrated the safety, tolerability, pharmacokinetics and pharmacokinetic characteristics of the product in humans. Subsequently, in April 2026, the Group obtained a drug clinical trial approval notice issued by the State Drug Administration for the use of this product for type 2 diabetes. It is expected that the product will show long-lasting hypoglycemic effects and clinical benefits in adult Chinese type 2 diabetics.

The clinical trial initiated this time is a multi-center, randomized, double-blind, placebo and positive-controlled, parallel-group phase II clinical trial aimed at evaluating the efficacy and safety of this product in adult type 2 diabetics under different dosing regimens. The recruitment and screening of participants for this phase II clinical trial is being actively promoted.